FYN–TRAF3IP2 Induces NF-κB Signaling-Driven Peripheral T-Cell Lymphoma

Consistent with a driver oncogenic role, FYN–TRAF3IP2 expression in hematopoietic progenitors induced NF-κB-driven T-cell transformation in mice and cooperated with loss of the Tet2 tumor suppressor in peripheral T-cell lymphoma development.
[Nature Cancer]
FYN – TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma | Nature Cancer. (n.d.). Retrieved January 22, 2021, from https://www.nature.com/articles/s43018-020-00161-w Cite
Abstract
Bookmark

No account yet? Register

0
Share

Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

Precision BioSciences, Inc. announced that the FDA has accepted the Investigational New Drug application for PBCAR19B, a next-generation, stealth cell, CD19 product candidate for patients with relapsed/refractory Non-Hodgkin Lymphoma.
[Precision BioSciences, Inc. (Globe Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Histone Methyltransferase WHSC1 Inhibits Colorectal Cancer Cell Apoptosis via Targeting Anti-Apoptotic BCL2

Scientists revealed how WHSC1 regulates tumorigenesis and chemosensitivity of colorectal cancer.
[Cell Death Discovery]
Wang, Y., Zhu, L., Guo, M., Sun, G., Zhou, K., Pang, W., Cao, D., Tang, X., & Meng, X. (2021). Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2. Cell Death Discovery, 7(1), 1–9. https://doi.org/10.1038/s41420-021-00402-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Circulating Tumor DNA Is Detectable in Canine Histiocytic Sarcoma, Oral Malignant Melanoma, and Multicentric Lymphoma

Researchers used droplet digital PCR or PCR for antigen receptor rearrangement, to explore tumor-specific point mutations, copy number alterations, and chromosomal rearrangements in the plasma of cancer-affected dogs. They detected circulating tumor DNA in 21/23 of histiocytic sarcoma, 2/8of oral melanoma, and 12/13 of lymphoma cases.
[Scientific Reports]
Prouteau, A., Denis, J. A., De Fornel, P., Cadieu, E., Derrien, T., Kergal, C., Botherel, N., Ulvé, R., Rault, M., Bouzidi, A., François, R., Dorso, L., Lespagnol, A., Devauchelle, P., Abadie, J., André, C., & Hédan, B. (2021). Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma. Scientific Reports, 11(1), 877. https://doi.org/10.1038/s41598-020-80332-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

CXCR5 CAR-T Cells Simultaneously Target B Cell Non-Hodgkin’s Lymphoma and Tumor-Supportive Follicular T Helper Cells

To target both B cell Non-Hodgkin’s lymphoma and follicular T helper cells in the tumor microenvironment, researchers applied a chimeric antigen receptor that recognized human CXCR5 with high avidity.
[Nature Communications]
Bunse, M., Pfeilschifter, J., Bluhm, J., Zschummel, M., Joedicke, J. J., Wirges, A., Stark, H., Kretschmer, V., Chmielewski, M., Uckert, W., Abken, H., Westermann, J., Rehm, A., & Höpken, U. E. (2021). CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells. Nature Communications, 12(1), 240. https://doi.org/10.1038/s41467-020-20488-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

AMOT Suppresses Tumor Progression via Regulating DNA Damage Response Signaling in Diffuse Large B-Cell Lymphoma

Researchers investigated the expression level and biological function of angiomotin (AMOT) in diffuse large B-cell lymphoma (DLBCL). AMOT expression was significantly reduced in DLBCL biopsy section, and low AMOT expression was associated with poor clinical prognosis.
[Cancer Gene Therapy]
Sang, T., Yang, J., Liu, J., Han, Y., Li, Y., Zhou, X., & Wang, X. (2021). AMOT suppresses tumor progression via regulating DNA damage response signaling in diffuse large B-cell lymphoma. Cancer Gene Therapy, 1–11. https://doi.org/10.1038/s41417-020-00258-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

ALK Ligand ALKAL2 Potentiates MYCN-Driven Neuroblastoma in the Absence of ALK Mutation

Scientists tested whether anaplastic lymphoma kinase AL2 (ALKAL2) ligand could potentiate neuroblastoma progression in the absence of ALK mutation
[EMBO Journal]
Borenäs, M., Umapathy, G., Lai, W.-Y., Lind, D. E., Witek, B., Guan, J., Mendoza-Garcia, P., Masudi, T., Claeys, A., Chuang, T.-P., El Wakil, A., Arefin, B., Fransson, S., Koster, J., Johansson, M., Gaarder, J., Van den Eynden, J., Hallberg, B., & Palmer, R. H. (2021). ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation. The EMBO Journal, n/a(n/a), e105784. https://doi.org/10.15252/embj.2020105784 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials

Zentalis Pharmaceuticals, Inc. announced that the company has initiated patient dosing in three new combination and monotherapy clinical trials.
[Zentalis Pharmaceuticals, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Combination of Anti-PD-1 Antibody with P-GEMOX as a Potentially Effective Immunochemotherapy for Advanced Natural Killer/T Cell Lymphoma

Scientists report the efficacy of anti-programmed death 1 antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) regimen in advanced natural killer/T cell lymphoma.
[Signal Transduction and Targeted Therapy]
Cai, J., Liu, P., Huang, H., Li, Y., Ma, S., Zhou, H., Tian, X., Zhang, Y., Gao, Y., Xia, Y., Zhang, X., Yang, H., Li, L., & Cai, Q. (2020). Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduction and Targeted Therapy, 5(1), 1–9. https://doi.org/10.1038/s41392-020-00331-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4

Investigators showed that positive coactivator 4 (PC4) orchestrated chromatin structure and gene expression in mature B cells. B-cell-specific PC4-deficient mice showed impaired production of antibody upon antigen stimulation.
[Cell Reports]
Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4: Cell Reports. (n.d.). Retrieved January 5, 2021, from https://www.cell.com/cell-reports/fulltext/S2211-1247(20)31506-0 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Targeting eIF4F Translation Initiation Complex with SBI-756 Sensitises B Lymphoma Cells to Venetoclax

Investigators tested inhibitors of cap-dependent mRNA translation for the ability to sensitise diffuse large B-cell lymphoma and mantle cell lymphoma cells to apoptosis by venetoclax.
[British Journal of Cancer]
Herzog, L., Walters, B., Buono, R., Lee, J. S., Mallya, S., Fung, A., Chiu, H., Nguyen, N., Li, B., Pinkerton, A. B., Jackson, M. R., Schneider, R. J., Ronai, Z. A., & Fruman, D. A. (2020). Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. British Journal of Cancer, 1–12. https://doi.org/10.1038/s41416-020-01205-9 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share